CytoSorb™

CytoSorbents’ primary focus is on the development of CytoSorb™.
 
CytoSorb™ acts by reduc­ing the level of cytokines, which trigger dangerous inflammation and immune system responses. Through the reduction of inflammatory mediators, the odds of recovery should be significantly improved.  

The first indication planned is an adjunctive therapy to the current standard of care for patients suffering from sepsis. Sepsis is characterized as a complex syndrome that is difficult to define, diagnose or treat. Sepsis can be caused by either cytokine production that increases to a level that  escapes the local infection site and enters the blood or when an infection such as bacteria enters the blood stream and triggers the immune response releasing large levels of cytokines. Victims of septic shock experience fever, falling blood pressure, myocardial suppression, headache, dehydration, renal failure, and respiratory arrest. Body organs fail and death may result from lethal septic shock. In turns out that the inflammatory responses can be more dangerous than the original inciting stimulus. We believe that CytoSorb™ reduces the amount of cytokines in the blood allowing a more normalized immune system response to fighting the primary infection, while also making other prescribed therapies more effective and producing better patient outcomes.

Each year, 1,000,000 people in the United States develop severe sepsis, with an estimated annual economic cost of $18 billion and 215,000 will die no matter how hard doctors fight to save them. Sepsis is triggered by the body’s own overpowering improper immune response to a systemic infection, and hospitals are the battlegrounds for these potentially lethal conditions. Given these statistics, CytoSorbents  Inc. believes that pending the outcome of further testing and required regulatory approval, there will be a large market for CytoSorb™.